Az Üzleti Sajtószolgálat (Original Text Service - OTS) üzleti vállakozások, cégek, intézmények közleményeit, tájékoztatóit, meghívóit, állásfoglalásait közli. Szolgáltatásunk segítségével több mint 2000 újságírót és kommunikációs szakembert érhet el könnyen, gyorsan és költséghatékonyan – az Ön által megfogalmazott sajtóközleményt változtatás nélkül juttatjuk el az MTI-előfizetők szerkesztőségi rendszerébe vagy igény szerint akár a külföldi sajtóhoz is. (Az OTS anyagai nem képezik az MTI-kiadás részét, a szó szerint továbbított szövegekért minden esetben a közlő a felelős.)
|
|
|
2017. március 30., csütörtök 12:05 |
Symetis and Boston Scientific reach USD 435 million purchase agreement |
|
Ecublens, Switzerland, 30 March, 2017 (APA/OTS) - Definitive purchase agreement whereby Boston Scientific will acquire Symetis for $435 million in an all cash, up-front payment - Acquisition of Symetis will expand the treatment offerings for patients with aortic valvular heart disease - Acquisition projected to close during the second quarter of 2017, subject to customary closing conditions - Symetis' IPO launched on Euronext Paris and very well received by the investment community, has been halted |
Symetis, a medical technology company specializing in the
development, manufacturing and marketing of percutaneous heart valve
replacement solutions for the treatment of severe cardiac valve
conditions, today announced that it has agreed to be acquired by
Boston Scientific for $435 million in an all cash, up-front payment.
The acquisition of Symetis by Boston Scientific will allow the
company to extend its reach and expand the treatment offerings for
patients with aortic valvular heart disease worldwide. The
combination of Symetis' ACURATE valves with the Boston Scientific
Lotus™ valve platform, will also enable interventional cardiologists
and cardiac surgeons to address varying patient pathologies and
anatomies with two complementary and compelling technologies.
Jacques R. Essinger, Ph.D. and CEO, Symetis, commented "Over the
past years, Symetis matured into a TAVI (Transcatheter Aortic Valve
Implantation) player with fast growth and a solid clinical
reputation. The IPO that we were pursuing until yesterday on
Euronext Paris was meant to give Symetis the means to commercially
expand beyond Europe and to further grow into the exciting field of
structural heart. We are very pleased by the positive response we
received from the investment community, which we want to thank for
the interest it has shown in Symetis. However, as of today, the
company is taking another path by joining Boston Scientific. The
global scale and strong legacy of Boston Scientific in
interventional cardiology will further propel Symetis' clinical
excellence. As a result, we can expect more patients to be better
treated for valvular heart disease globally. Moving forward, this
means an exciting development path for the Symetis team."
Dominik Ellenrieder, Symetis' Chairman, added "Growing at a strong
and sustained CAGR of 55% since 2012, Symetis is a success story in
the structural heart market. This purchase agreement is a
recognition of Symetis' research and development track record in
addressing patients' needs with innovative structural heart
technologies, the company's manufacturing expertise and its strong
relationships with doctors and healthcare professionals. We are
excited about the strong potential of our combined strengths to set
a new standard in the TAVI market with a broad and clinically
differentiated offering."
Following the purchase agreement reached with Boston Scientific,
the IPO launched on 20 March 2017 by Symetis on Euronext Paris, very
well received by the investment community and which was originally
expected to be completed on 31 March 2017, has been halted. The
acquisition of Symetis by Boston Scientific is projected to close
during the second quarter of 2017, subject to customary closing
conditions.
Contact Symetis Khaled Bahi - Chief Financial Officer +41 (0) 21 651 01 60 investors@symetis.com
Weber Shandwick Alphonse Daudré-Vignier +41 (0) 79 127 63 58 adaudre-vignier@webershandwick.com
About Symetis
Symetis, founded in 2001, is a medical technology company
specializing in the development, manufacturing and marketing of
percutaneous heart valve replacement solutions for the treatment of
severe cardiac valve conditions.
Symetis' products, ACURATE TA™ and ACURATE neo/TF, and their
delivery systems are based on proprietary design and delivery
technologies and are marketed and sold in key markets in Europe and
in other geographies. Symetis' innovative TAVI solutions are
recognized by intervention cardiologists and surgeons for their
clinical performance and ease of use.
Growing at a strong and sustained CAGR of 55% since 2012, the
company generated revenues of CHF 38.4 million in 2016.
Symetis is a Swiss company with corporate headquarters in Ecublens,
Switzerland and its products are produced in Switzerland and Brazil.
For more information visit http://www.symetis.com
-------------------------------------------------------------------
Az OTS internetes oldalán található hírek, közlemények, fotók
a forrásmegjelöléssel (OTS) szabadon és korlátozás nélkül
felhasználhatók. Továbbközlés esetén a közzétevő köteles az átvett
anyagot tartalmának torzítása nélkül, félreérthetőséget,
rosszindulatú következtetéseket kizáró, az eredeti
szövegkörnyezetnek megfelelő módon feldolgozni és megjelentetni.
Az OTS hírek nem képezik az MTI hírkiadás részét, az MTI
által szó szerint továbbított tartalomért minden esetben a beadó a
felelős. © Copyright MTI nonprofit Zrt.
Az OTS szolgáltatással kapcsolatban további információt a
(06-1) 441-9050 telefonszámon vagy a ots@mti.hu elektronikus
levelező címen kaphat.
|
|
|
|
|
|
|
|
|
|
|